{"nctId":"NCT00354341","briefTitle":"(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy","startDateStruct":{"date":"2002-09"},"conditions":["Anemia"],"count":170,"armGroups":[{"label":"Group 1 (Early Epoetin Beta)","type":"EXPERIMENTAL","interventionNames":["Drug: Epoetin beta"]},{"label":"Group 2 (No/Late Epoetin Beta)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Epoetin beta"]}],"interventions":[{"name":"Epoetin beta","otherNames":["NeoRecormon"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients \\>=18 years of age;\n* type 1 or type 2 diabetes;\n* stable glycemic control for \\>=3 months;\n* diabetic nephropathy.\n\nExclusion Criteria:\n\n* women who are pregnant, breastfeeding, or unwilling to use a reliable contraceptive method;\n* previous treatment with erythropoietin or other erythropoietic substance;\n* nondiabetic renal disease, nephrotic syndrome;\n* blood transfusion within the 3 months prior to enrollment;\n* administration of any investigational drug within 30 days preceding the study start, and during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15","description":"LVMI (in g/m\\^2) = (0.8 \\[1.04 {(LVEDD + IVS + PWT)\\^3 - (LVEDD)\\^3}\\] + 0.6) divided by BSA. Here, LVEDD = left ventricular end diastolic diameter (in centimeters \\[cm\\]); PWT = left ventricular posterior wall thickness in diastole (in cm); IVS = interventricular septal wall thickness in diastole (in cm). Echocardiogram was performed at baseline and Month 15 to interpret LVMI which was expressed in grams per meter square (g/m\\^2).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"26.34"},{"groupId":"OG001","value":"0.10","spread":"24.25"}]}]}]},{"type":"SECONDARY","title":"Left Ventricular End Systolic Volume Index (LVESVI)","description":"LVESVI was calculated by dividing left ventricular end systolic volume (LVESV) (in milliliters \\[mL\\]) with body surface area (BSA) (in meter square \\[m\\^2\\]). LVESVI is presented in milliliter per meter square (mL/m\\^2).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.40","spread":"6.36"},{"groupId":"OG001","value":"21.04","spread":"5.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.86","spread":"8.21"},{"groupId":"OG001","value":"24.54","spread":"8.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.99","spread":"9.31"},{"groupId":"OG001","value":"25.03","spread":"6.88"}]}]}]},{"type":"SECONDARY","title":"Left Ventricular End Diastolic Volume Index (LVEDVI)","description":"LVEDVI was calculated by dividing left ventricular end diastolic volume (LVEDV) (in mL) BSA (in m\\^2). LVEDVI was presented in mL/m\\^2.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.08","spread":"12.69"},{"groupId":"OG001","value":"58.13","spread":"10.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.74","spread":"15.41"},{"groupId":"OG001","value":"60.40","spread":"12.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.26","spread":"16.27"},{"groupId":"OG001","value":"62.07","spread":"11.36"}]}]}]},{"type":"SECONDARY","title":"Fractional Myocardial Shortening (FS)","description":"FS was calculated as: (\\[LVEDD - LVESD\\] divided by LVEDV) multiplied by 100; where LVEDD = left ventricular end diastolic diameter (in centimeters \\[cm\\]), LVESD = left ventricular end systolic diameter (in cm), LVEDV = left ventricular end diastolic volume (in mL). FS is expressed in percentage of LVEDV.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.45","spread":"7.80"},{"groupId":"OG001","value":"36.58","spread":"8.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.80","spread":"7.40"},{"groupId":"OG001","value":"38.49","spread":"7.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.58","spread":"7.01"},{"groupId":"OG001","value":"38.86","spread":"7.52"}]}]}]},{"type":"SECONDARY","title":"Left Ventricular Ejection Fraction (LVEF)","description":"LVEF was calculated as (\\[LVEDV - LVESV\\], divided by LVEDV) multiplied by 100; where LVEDV = left ventricular end diastolic volume (in mL), LVESV = left ventricular end systolic volume (in mL). LVEF is expressed in percentage of LVEDV.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.44","spread":"5.73"},{"groupId":"OG001","value":"63.84","spread":"5.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.22","spread":"6.87"},{"groupId":"OG001","value":"59.92","spread":"7.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.63","spread":"6.47"},{"groupId":"OG001","value":"59.97","spread":"6.46"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":88},"commonTop":["Hypertension","Edema peripheral","Renal impairment","Nasopharyngitis"]}}}